Your browser is no longer supported. Please, upgrade your browser.
Settings
NTLA [NASD]
Intellia Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.46 Insider Own1.20% Shs Outstand67.18M Perf Week4.85%
Market Cap9.66B Forward P/E- EPS next Y-2.87 Insider Trans-67.87% Shs Float64.74M Perf Month-15.22%
Income-148.60M PEG- EPS next Q-0.63 Inst Own83.00% Short Float5.25% Perf Quarter92.76%
Sales51.50M P/S187.51 EPS this Y-13.80% Inst Trans-0.35% Short Ratio1.52 Perf Half Y96.81%
Book/sh8.13 P/B17.07 EPS next Y-7.50% ROA-25.40% Target Price138.44 Perf Year620.99%
Cash/sh8.39 P/C16.54 EPS next 5Y30.00% ROE-33.90% 52W Range16.54 - 202.73 Perf YTD155.13%
Dividend- P/FCF- EPS past 5Y-46.70% ROI- 52W High-32.82% Beta2.12
Dividend %- Quick Ratio9.90 Sales past 5Y57.20% Gross Margin- 52W Low723.46% ATR12.23
Employees312 Current Ratio9.90 Sales Q/Q-50.40% Oper. Margin- RSI (14)52.66 Volatility6.16% 7.16%
OptionableYes Debt/Eq0.00 EPS Q/Q-9.20% Profit Margin- Rel Volume0.56 Prev Close138.79
ShortableYes LT Debt/Eq0.00 EarningsAug 05 BMO Payout- Avg Volume2.24M Price136.20
Recom2.10 SMA20-3.98% SMA5020.64% SMA20089.24% Volume557,133 Change-1.87%
Jun-28-21Reiterated H.C. Wainwright Buy $111 → $171
Jun-11-21Initiated H.C. Wainwright Buy $111
May-07-21Upgrade ROTH Capital Neutral → Buy $75 → $80
May-04-21Initiated RBC Capital Mkts Outperform $110
Mar-04-21Initiated JMP Securities Mkt Outperform $80
Dec-22-20Downgrade Robert W. Baird Outperform → Neutral $60
Oct-27-20Initiated Truist Buy $40
Oct-14-20Initiated Wells Fargo Overweight
Sep-18-20Initiated Goldman Buy $33
Feb-28-20Upgrade Oppenheimer Perform → Outperform
Feb-14-20Downgrade Wedbush Outperform → Neutral $16
Nov-01-19Upgrade Raymond James Mkt Perform → Outperform
Jul-09-19Initiated Robert W. Baird Outperform $23
Jun-10-19Initiated ROTH Capital Neutral $16
May-03-19Upgrade Wedbush Neutral → Outperform $20 → $21
Apr-12-19Initiated Evercore ISI Outperform
Nov-02-18Downgrade Wedbush Outperform → Neutral $36 → $20
Oct-29-18Initiated Credit Suisse Neutral $24
Sep-21-18Initiated Raymond James Mkt Perform
May-15-18Upgrade Chardan Capital Markets Neutral → Buy $20 → $57.50
Aug-02-21 08:52AM  
Jul-29-21 03:05PM  
07:30AM  
Jul-27-21 05:50PM  
Jul-16-21 11:02AM  
05:32AM  
Jul-15-21 08:19AM  
Jul-12-21 03:12PM  
Jul-11-21 07:01AM  
Jul-10-21 05:19AM  
Jul-09-21 04:04PM  
Jul-06-21 11:28AM  
Jul-04-21 07:49AM  
Jul-02-21 04:35PM  
04:01PM  
12:48PM  
Jul-01-21 06:56AM  
Jun-30-21 10:14PM  
04:20PM  
04:04PM  
03:30PM  
01:14PM  
12:14PM  
11:32AM  
08:46AM  
06:47AM  
06:42AM  
Jun-29-21 09:08PM  
11:20AM  
09:55AM  
09:34AM  
06:58AM  
05:15AM  
Jun-28-21 04:25PM  
04:12PM  
04:01PM  
02:36PM  
01:17PM  
12:22PM  
12:17PM  
11:09AM  
10:39AM  
10:02AM  
10:00AM  
09:15AM  
08:41AM  
08:39AM  
06:09AM  
05:34AM  
04:52AM  
04:06AM  
03:19AM  
Jun-27-21 07:25AM  
Jun-26-21 08:00PM  
01:07PM  
11:16AM  
Jun-25-21 04:45AM  
Jun-24-21 07:30AM  
Jun-22-21 07:00AM  
06:41AM  
Jun-07-21 07:11AM  
Jun-04-21 07:30AM  
Jun-03-21 07:39AM  
Jun-02-21 09:40AM  
Jun-01-21 03:41AM  
May-11-21 12:12PM  
May-07-21 06:00PM  
May-06-21 08:50AM  
07:30AM  
06:15AM  
Apr-30-21 11:15AM  
Apr-29-21 05:05PM  
07:30AM  
Apr-28-21 05:30AM  
Apr-27-21 04:35PM  
Apr-16-21 03:51PM  
Apr-14-21 12:30PM  
Apr-12-21 07:30AM  
Mar-30-21 07:30AM  
Mar-25-21 07:30AM  
Mar-10-21 07:30AM  
Mar-03-21 01:46AM  
Feb-27-21 09:23AM  
Feb-26-21 12:59AM  
Feb-25-21 09:30PM  
07:30AM  
05:45AM  
Feb-18-21 07:30AM  
Jan-29-21 09:44AM  
Jan-20-21 08:23AM  
Jan-15-21 06:12PM  
Jan-14-21 03:11PM  
Jan-11-21 08:02AM  
Jan-08-21 09:01AM  
Jan-07-21 04:24PM  
01:05PM  
08:42AM  
07:30AM  
Jan-06-21 11:00AM  
Jan-04-21 09:27AM  
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; and Ospedale San Raffaele. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FORMELA JEAN FRANCOISDirectorJun 28Sale132.73553,37673,448,87910,000Jun 29 09:48 AM
FORMELA JEAN FRANCOISDirectorJun 14Sale87.37170,77914,921,294563,376Jun 15 09:51 AM
FORMELA JEAN FRANCOISDirectorJun 11Sale85.2330,9462,637,480734,155Jun 15 09:51 AM
FORMELA JEAN FRANCOISDirectorApr 29Sale85.434,513385,546765,101Apr 30 08:55 PM
FORMELA JEAN FRANCOISDirectorApr 28Sale85.56131,92611,287,893769,614Apr 28 07:51 PM
FORMELA JEAN FRANCOISDirectorApr 27Sale86.22210,23018,125,992901,540Apr 28 07:51 PM
FORMELA JEAN FRANCOISDirectorApr 26Sale84.9380668,4541,111,770Apr 28 07:51 PM
LEONARD JOHN MPresident and CEOApr 13Option Exercise11.1625,937289,506719,305Apr 15 08:50 PM
DORSA CAROLINEDirectorApr 05Option Exercise6.407,50048,00012,910Apr 06 06:09 PM
FORMELA JEAN FRANCOISDirectorApr 05Sale84.9880067,9841,112,576Apr 07 02:14 PM
DORSA CAROLINEDirectorApr 05Sale82.197,500616,4055,410Apr 06 06:09 PM
Rivera Jose EEVP, General CounselApr 01Option Exercise12.5197,0011,213,537178,077Apr 02 08:42 PM
LEONARD JOHN MPresident and CEOApr 01Option Exercise14.1571,0411,005,049707,263Apr 02 08:46 PM
LEONARD JOHN MPresident and CEOApr 01Sale83.6438,2093,195,661681,222Apr 02 08:46 PM
Rivera Jose EEVP, General CounselApr 01Sale82.4650,4554,160,559131,032Apr 02 08:42 PM
FORMELA JEAN FRANCOISDirectorFeb 26Sale60.29501,94530,262,7161,113,376Mar 01 01:59 PM
LEONARD JOHN MPresident and CEOFeb 09Option Exercise6.8356,718387,384688,579Feb 09 08:36 PM
Rivera Jose EEVP, General CounselFeb 09Option Exercise18.3021,000384,195129,409Feb 09 08:38 PM
LEONARD JOHN MPresident and CEOFeb 09Sale75.0028,0432,103,225660,536Feb 09 08:36 PM
Rivera Jose EEVP, General CounselFeb 09Sale75.0011,489861,675117,920Feb 09 08:38 PM
LEONARD JOHN MPresident and CEOFeb 05Option Exercise13.4040,000536,000654,803Feb 09 08:36 PM
LEONARD JOHN MPresident and CEOFeb 05Sale67.6622,9421,552,185631,861Feb 09 08:36 PM
LEONARD JOHN MPresident and CEOFeb 03Option Exercise17.68117,0602,069,793651,661Feb 03 09:39 PM
LEONARD JOHN MPresident and CEOFeb 03Sale72.5467,8564,922,490584,601Feb 03 09:39 PM
Rivera Jose EEVP, General CounselFeb 01Option Exercise9.68109,0001,054,620121,686Feb 03 09:38 PM
LEONARD JOHN MPresident and CEOFeb 01Option Exercise13.69200,0002,737,600598,814Feb 03 09:39 PM
Rivera Jose EEVP, General CounselFeb 01Sale63.9954,6593,497,90288,686Feb 03 09:38 PM
LEONARD JOHN MPresident and CEOFeb 01Sale64.00109,8897,032,905523,853Feb 03 09:39 PM
Cohen Fred EDirectorJan 20Option Exercise13.7820,000275,60030,000Jan 22 04:22 PM
Rivera Jose EEVP, General CounselJan 05Sale55.862,078116,07751,990Jan 05 08:55 PM
SCHIERMEIER ANDREWEVP, Chief Operating OfficerJan 05Sale55.861,37776,91916,656Jan 05 08:58 PM
LEONARD JOHN MPresident and CEOJan 05Sale55.866,239348,511475,488Jan 05 09:24 PM
LEONARD JOHN MPresident and CEODec 31Option Exercise0.0014,3750481,727Jan 05 09:24 PM
SCHIERMEIER ANDREWEVP, Chief Operating OfficerDec 31Option Exercise0.004,792018,033Jan 05 08:58 PM
Rivera Jose EEVP, General CounselDec 31Option Exercise0.004,792054,068Jan 05 08:55 PM
SCHIERMEIER ANDREWEVP, Chief Operating OfficerDec 30Option Exercise13.481,50020,22012,673Jan 04 09:03 PM
KARSEN PERRY ADirectorDec 17Option Exercise18.4588,7641,637,84293,764Dec 18 04:29 PM
KARSEN PERRY ADirectorDec 17Sale53.5588,7644,753,6805,000Dec 18 04:29 PM
Rivera Jose EEVP, General CounselDec 01Option Exercise13.885,00069,40052,072Dec 03 06:42 PM
Rivera Jose EEVP, General CounselDec 01Sale38.213,364128,52548,708Dec 03 06:42 PM
LEONARD JOHN MPresident and CEONov 27Option Exercise16.1735,000566,100487,352Nov 27 09:00 PM
LEONARD JOHN MPresident and CEONov 27Sale38.5735,0001,350,000467,352Nov 27 09:00 PM
LEONARD JOHN MPresident and CEONov 25Option Exercise6.8350,000341,500517,352Nov 25 08:02 PM
LEONARD JOHN MPresident and CEONov 25Sale36.0050,0001,800,000467,352Nov 25 08:02 PM
Rivera Jose EEVP, General CounselNov 18Option Exercise18.3084815,51847,696Nov 18 07:55 PM
Rivera Jose EEVP, General CounselNov 18Sale35.0062421,84047,072Nov 18 07:55 PM
Rivera Jose EEVP, General CounselNov 16Option Exercise7.4410,56278,58552,315Nov 18 07:55 PM
LEONARD JOHN MPresident and CEONov 16Option Exercise14.5820,000291,600487,352Nov 18 07:56 PM
LEONARD JOHN MPresident and CEONov 16Sale34.0020,000680,000467,352Nov 18 07:56 PM
Rivera Jose EEVP, General CounselNov 16Sale34.296,029206,72846,700Nov 18 07:55 PM
LEONARD JOHN MPresident and CEONov 04Option Exercise6.8350,000341,500517,352Nov 06 04:38 PM
Rivera Jose EEVP, General CounselNov 04Option Exercise13.885,00069,40045,679Nov 06 04:41 PM
Rivera Jose EEVP, General CounselNov 04Sale28.003,36494,19242,315Nov 06 04:41 PM
LEONARD JOHN MPresident and CEONov 04Sale26.0050,0001,300,000467,352Nov 06 04:38 PM
Rivera Jose EEVP, General CounselOct 15Option Exercise6.8310,00068,30046,294Oct 16 08:58 PM
Rivera Jose EEVP, General CounselOct 15Sale24.205,615135,88340,679Oct 16 08:58 PM
LEONARD JOHN MPresident and CEOOct 07Option Exercise6.835,00034,150472,352Oct 09 04:14 PM
LEONARD JOHN MPresident and CEOOct 07Sale21.835,000109,150467,352Oct 09 04:14 PM
Rivera Jose EEVP, General CounselSep 15Option Exercise6.8310,00068,30041,909Sep 17 04:55 PM
Rivera Jose EEVP, General CounselSep 15Sale21.045,615118,14036,294Sep 17 04:55 PM
LEONARD JOHN M.President and CEOSep 01Option Exercise6.835,00034,150472,352Sep 03 04:15 PM
LEONARD JOHN M.President and CEOSep 01Sale21.835,000109,150467,352Sep 03 04:15 PM
Rivera Jose EEVP, General CounselAug 18Option Exercise6.8310,00068,30037,524Aug 20 04:13 PM
Rivera Jose EEVP, General CounselAug 18Sale21.005,615117,91531,909Aug 20 04:13 PM
LEONARD JOHN M.President and CEOAug 06Option Exercise6.835,00034,150472,352Aug 07 07:29 PM
LEONARD JOHN M.President and CEOAug 06Sale21.835,000109,150467,352Aug 07 07:29 PM